High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Liu, Guoliang ^a   Huang, Xiaodong ^a   Cui, Xiaopeng ^a   Zhang, Jing ^a   Wei, Lixian ^a   Ni, Runzhou ^a   Lu, Cuihua ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Prognosis; Proliferation; Ski interacting protein (SKIP)

Indexed keywords

KI 67 ANTIGEN; SKI INTERACTING PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SKIP PROTEIN, HUMAN;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; YOUNG ADULT; CELL CYCLE CHECKPOINT; CELL CYCLE S PHASE; GENETICS; LIVER TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; HEPG2 CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; FEMALE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; S PHASE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84877911775     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0537-4     Document Type: Article

References (26)

1. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134(6):1752-63.
2. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448-58.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118- 27.
4. Hur W, Rhim H, Jung CK, et al. SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro. Carcinogenesis. 2010;31(7):1298-307.
5. Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136(2):275-81.
6. Lipinski MM, Jacks T. The retinoblastoma gene family in differentiation and development. Oncogene. 1999;18:7873-82.
7. Harbour JW, Dean DC. Rb function in cell cycle regulation and apoptosis. Nat Cell Biol. 2000;2:E65-7.
8. Dahl R, Wani B, Hayman MJ. The Ski oncoprotein interacts with Skip, the human homolog of Drosophila Bx42. Oncogene. 1998;16(12):1579-86.
9. Leong GM, Subramaniam N, Figueroa J, et al. Ski-interacting protein interacts with Smad proteins to augment transforming growth factor-beta- dependent transcription. J Biol Chem. 2001;276(21):18243-8.
10. Prathapam T, Kuhne C, Banks L. Skip interacts with the retinoblastoma tumor suppressor and inhibits its transcriptional repression activity. Nucleic Acids Res. 2002;30(23):5261-8.
11. Folk P, Puta F, Skruzny M. Transcriptional coregulator SNW/SKIP: the concealed tie of dissimilar pathways. Cell Mol Life Sci. 2004;61(6):629-40.
12. Obama K, Kato T, Hasegawa S, Satoh S, Nakamura Y, Furukawa Y. Overexpression of peptidyl-prolyl isomerase-like 1 is associated with the growth of colon cancer cells. Clin Cancer Res. 2006;12(1):70-6.
13. Xu C, Zhang J, Huang X, et al. Solution structure of human peptidyl prolyl isomerase-like protein 1 and insights into its interaction with SKIP. J Biol Chem. 2006;281(23):15900-8.
14. Ke Q, Ji J, Cheng C, et al. Expression and prognostic role of Spy1 as a novel cell cycle protein in hepatocellular carcinoma. Exp Mol Pathol. 2009;87(3):167-72.
15. Xu X, Yamamoto H, Sakon M, et al. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin Cancer Res. 2003;9(5):1764-72.
16. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-17.
17. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-76.
18. Chen Y, Zhang L, Jones KA. SKIP counteracts p53-mediated apoptosis via selective regulation of p21Cip1 mRNA splicing. Genes Dev. 2011;25(7):701-16.
19. Kitamoto M, Nakanishi T, Kira S, et al. The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer. 1993;72(6):1859-65.
20. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43(6):979-92.
21. Liu S, Dong Q, Wang E. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer. Tumour Biol. 2012;33(5):1485-91.
22. Deng Q, Wang Q, Zong WY, et al. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. Cancer Res. 2010;70(2):782-91.
23. Emori TK, Kitamura K, Okazaki K. Nuclear Smad7 overexpressed in mesenchymal cells acts as a transcriptional corepressor by interacting with HDAC-1 and E2F to regulate cell cycle. Biol Open. 2012;1(3):247-60.
24. Han Y, He H, Peng F, et al. SKLB70326, a novel small-molecule inhibitor of cell-cycle progression, induces G(0)/G(1) phase arrest and apoptosis in human hepatic carcinoma cells. Biochem Biophys Res Commun. 2012;421(4):684-9.
25. Muller H, Helin K. The E2F transcription factors: key regulators of cell proliferation. Biochim Biophys Acta. 2000;1470:M1-12.
26. Lu ZL, Luo DZ, Wen JM. Expression and significance of tumorrelated genes in HCC. World J Gastroenterol. 2005;11:3850-4.